Akcea Therapeutics Inc (AKCA) Receives a Hold from Stifel Nicolaus

By Carrie Williams

In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on Akcea Therapeutics Inc (NASDAQ: AKCA). The company’s shares closed yesterday at $34.19, close to its 52-week high of $38.06.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.5% and a 50.7% success rate. Willey covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Lexicon Pharmaceuticals, and Spark Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akcea Therapeutics Inc with a $35.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $38.06 and a one-year low of $13.70. Currently, Akcea Therapeutics Inc has an average volume of 294.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akcea Therapeutics, Inc. is a late-stage pharmaceutical company, which engages in the development and commercializing of drugs fro the treatment of cardio metabolic diseases caused by lipid disorders. Its products include novel drugs under the followng brands: volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx.